[144] Abbott Laboratories SEC Filing

Rhea-AI Filing Summary

Abbott Laboratories (ABT) filed a Form 144 proposing the sale of 5,550 shares of common stock. The notice states the shares have an aggregate market value of $746,758.27 and lists total outstanding shares of 1,740,459,014. The proposed sale is to be executed through UBS Financial Services on the NYSE with an approximate sale date of 08/08/2025.

The filing shows all 5,550 shares were acquired by the filer as vested restricted stock awards on 02/28/2022 (1,801 shares), 02/28/2023 (3,559 shares), and 02/29/2024 (190 shares). The form reports "Nothing to Report" for securities sold in the past three months and includes the standard signature representation about absence of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Small, routine Form 144 filing showing proposed sale of vested restricted shares through a broker on the NYSE.

The filing documents a proposed sale of 5,550 common shares valued at $746,758.27, to be executed via UBS on 08/08/2025. The shares were acquired through vested restricted stock awards on three separate dates. There are no reported sales in the past three months. For investors, this filing is a disclosure of an insider-origin sale but contains no operational or financial performance information about the issuer.

Corporate Governance Expert

TL;DR: Administrative disclosure of insider sale under Rule 144; reflects compensation vesting and planned market sale via a broker.

The notice identifies the nature of acquisition as Restricted Stock Award Vested with specific grant dates and quantities, and specifies the broker and exchange for the planned disposition. The form includes the required representation that the seller is not aware of undisclosed material adverse information. This is a compliance-driven filing rather than a corporate-governance event altering control or strategy.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	5550	746758.27	1740459014	08/08/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2022	Restricted Stock Award Vested	Issuer			1801	08/08/2025	N/A
Common	02/28/2023	Restricted Stock Award Vested	Issuer			3559	08/08/2025	N/A
Common	02/29/2024	Restricted Stock Award Vested	Issuer			190	08/08/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)